CN103197067A - 显示cd44表面表达的细胞的细胞毒性介导 - Google Patents

显示cd44表面表达的细胞的细胞毒性介导 Download PDF

Info

Publication number
CN103197067A
CN103197067A CN2013100529947A CN201310052994A CN103197067A CN 103197067 A CN103197067 A CN 103197067A CN 2013100529947 A CN2013100529947 A CN 2013100529947A CN 201310052994 A CN201310052994 A CN 201310052994A CN 103197067 A CN103197067 A CN 103197067A
Authority
CN
China
Prior art keywords
cancer
antibody
cells
cell
antibodies
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2013100529947A
Other languages
English (en)
Chinese (zh)
Inventor
大卫·S·F·杨
海伦·P·芬德利
苏姗·E·哈恩
利萨·M·切凯托
福尔图纳塔·麦康基
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Arius Research Inc
Original Assignee
Arius Research Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arius Research Inc filed Critical Arius Research Inc
Publication of CN103197067A publication Critical patent/CN103197067A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2884—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD44
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6891—Pre-targeting systems involving an antibody for targeting specific cells
    • A61K47/6897—Pre-targeting systems with two or three steps using antibody conjugates; Ligand-antiligand therapies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
    • A61K49/0058—Antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5082—Supracellular entities, e.g. tissue, organisms
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/5759—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds localised on the membrane of tumour or cancer cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70585—CD44

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Cell Biology (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Organic Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Nanotechnology (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CN2013100529947A 2006-02-28 2007-02-23 显示cd44表面表达的细胞的细胞毒性介导 Pending CN103197067A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11/364,013 2006-02-28
US11/364,013 US7947496B2 (en) 1999-10-08 2006-02-28 Cytotoxicity mediation of cells evidencing surface expression of CD44

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN2007800154239A Division CN101432307B (zh) 2006-02-28 2007-02-23 显示cd44表面表达的细胞的细胞毒性介导

Publications (1)

Publication Number Publication Date
CN103197067A true CN103197067A (zh) 2013-07-10

Family

ID=38458603

Family Applications (2)

Application Number Title Priority Date Filing Date
CN2013100529947A Pending CN103197067A (zh) 2006-02-28 2007-02-23 显示cd44表面表达的细胞的细胞毒性介导
CN2007800154239A Expired - Fee Related CN101432307B (zh) 2006-02-28 2007-02-23 显示cd44表面表达的细胞的细胞毒性介导

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN2007800154239A Expired - Fee Related CN101432307B (zh) 2006-02-28 2007-02-23 显示cd44表面表达的细胞的细胞毒性介导

Country Status (15)

Country Link
US (3) US7947496B2 (https=)
EP (2) EP2508536A1 (https=)
JP (2) JP5247474B2 (https=)
CN (2) CN103197067A (https=)
AU (1) AU2007219656B2 (https=)
CA (1) CA2643708A1 (https=)
CY (1) CY1115212T1 (https=)
DK (1) DK1989233T3 (https=)
ES (1) ES2444408T3 (https=)
NZ (1) NZ570776A (https=)
PL (1) PL1989233T3 (https=)
PT (1) PT1989233E (https=)
SI (1) SI1989233T1 (https=)
TW (1) TW200731987A (https=)
WO (1) WO2007098575A1 (https=)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109402064A (zh) * 2018-11-05 2019-03-01 湖南省肿瘤医院 杂交瘤细胞株及其产生的单克隆抗体和应用
CN114250200A (zh) * 2021-12-23 2022-03-29 蚌埠医学院 一种非小细胞肺癌脑转移和脊髓转移的动物模型构建方法

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090004103A1 (en) * 1999-10-08 2009-01-01 Young David S F Cytotoxicity mediation of cells evidencing surface expression of CD44
US8048416B2 (en) * 1999-10-08 2011-11-01 Hoffmann-La Roche Inc. Cytotoxicity mediation of cells evidencing surface expression of CD44
US8071072B2 (en) 1999-10-08 2011-12-06 Hoffmann-La Roche Inc. Cytotoxicity mediation of cells evidencing surface expression of CD44
US20080124327A1 (en) * 1999-10-08 2008-05-29 Arius Research, Inc. Cytotoxicity mediation of cells evidencing surface expression of CD44
US7947496B2 (en) * 1999-10-08 2011-05-24 Hoffmann-La Roche Inc. Cytotoxicity mediation of cells evidencing surface expression of CD44
US7419792B2 (en) * 1999-10-08 2008-09-02 Arius Research Inc. Laminin Receptor 1 Precursor Protein (37LRP) epitope delineated by an Hepatocellular carcinoma specific antibody
US20050100542A1 (en) * 1999-10-08 2005-05-12 Young David S. Cytotoxicity mediation of cells evidencing surface expression of CD44
CN101663049A (zh) * 2007-03-09 2010-03-03 霍夫曼-拉罗奇有限公司 证明cd44表面表达的细胞的细胞毒性介导
EP2009028A1 (en) * 2007-06-27 2008-12-31 Monoclonal Antibodies Therapeutics Combination of a conventional anti-cancer treatment with anti-CD44 antibody administration for treating solid tumors
EP2547693B1 (en) 2010-03-19 2015-03-11 H. Lee Moffitt Cancer Center & Research Institute Integrin interaction inhibitors for the treatment of cancer
WO2012129335A2 (en) * 2011-03-21 2012-09-27 H. Lee Moffitt Cancer Center And Research Institute, Inc Hyd1 peptides for relapsed cancer
EP2749641B1 (en) 2011-09-07 2021-06-02 Chugai Seiyaku Kabushiki Kaisha Cancer stem cell isolation
US10011635B2 (en) 2013-09-27 2018-07-03 H. Lee Moffitt Cancer Center And Research Institute, Inc. Cyclic peptide conjugates and methods of use
WO2020084034A1 (en) 2018-10-26 2020-04-30 F. Hoffmann-La Roche Ag Multispecific antibody screening method using recombinase mediated cassette exchange
CN112569351B (zh) * 2020-12-16 2021-10-15 南通大学 Cd44抗体在制备治疗帕金森疾病的药物中的应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1152925A (zh) * 1994-06-08 1997-06-25 贝林格尔·英格海姆国际有限公司 抗cd44v6单克隆抗体
WO2005018667A1 (en) * 2003-08-22 2005-03-03 Arius Research, Inc. Cytotoxicity mediation of cells evidencing surface expression of cd44
WO2005083063A1 (en) * 2004-02-26 2005-09-09 Arius Research, Inc. Cancerous disease modifying antibodies

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US486158A (en) 1892-11-15 John cook
US4172124A (en) 1978-04-28 1979-10-23 The Wistar Institute Method of producing tumor antibodies
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4828991A (en) 1984-01-31 1989-05-09 Akzo N.V. Tumor specific monoclonal antibodies
EP0266032A1 (en) 1986-08-29 1988-05-04 Beecham Group Plc Modified fibrinolytic enzyme
NZ222509A (en) 1986-11-19 1993-03-26 Oncogen Hybridoma cell line producing antibodies binding to tumour-associated mucin antigen
US4861581A (en) 1986-12-05 1989-08-29 Cancer Biologics, Inc. Detection of necrotic malignant tissue and associated therapy
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5171665A (en) 1989-04-17 1992-12-15 Oncogen Monoclonal antibody to novel antigen associated with human tumors
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US6020145A (en) 1989-06-30 2000-02-01 Bristol-Myers Squibb Company Methods for determining the presence of carcinoma using the antigen binding region of monoclonal antibody BR96
US5980896A (en) * 1989-06-30 1999-11-09 Bristol-Myers Squibb Company Antibodies reactive with human carcinomas
DE4014510A1 (de) 1990-05-07 1991-11-14 Kernforschungsz Karlsruhe Variante cd44-oberflaechenproteine, diese kodierende c-dna-sequenzen, antikoerper gegen diese proteine sowie ihre verwendung in der diagnostik und therapie
EP1400536A1 (en) 1991-06-14 2004-03-24 Genentech Inc. Method for making humanized antibodies
EP0539970B1 (en) 1991-10-30 1999-05-26 Idemitsu Kosan Company Limited Methods for producing human lymphocytes and human monoclonal antibodies, and human monoclonal antibodies produced thereby
ATE207080T1 (de) 1991-11-25 2001-11-15 Enzon Inc Multivalente antigen-bindende proteine
IL105008A0 (en) 1992-03-13 1993-07-08 Yeda Res & Dev Double transfectants of mhc genes as cellular vaccines for immunoprevention of tumor metastasis
CA2149635A1 (en) 1992-11-20 1994-06-09 David Tarin Peptide corresponding to cd44 exon 6, antibodies specific for said peptide and use of these antibodies for diagnosis of tumors
US5879898A (en) * 1992-11-20 1999-03-09 Isis Innovation Limited Antibodies specific for peptide corresponding to CD44 exon 6, and use of these antibodies for diagnosis of tumors
EP0686260B1 (en) 1993-02-05 2003-07-09 Epigen, Inc. Human carcinoma antigen (hca), hca antibodies, hca immunoassays, methods of imaging and therapy
US5693322A (en) 1993-03-11 1997-12-02 The United States Of America As Represented By The Department Of Health And Human Services Enhanced intercellular interaction by associational antibody molecules
ATE159953T1 (de) 1993-06-18 1997-11-15 Biotie Therapies Oy Zusammensetzungen und diagnostische verfahren unter verwendung von monoklonalen antikoerpern gegen cd44v6
DE69534347T2 (de) 1994-01-31 2006-05-24 Trustees Of Boston University, Boston Bibliotheken aus Polyklonalen Antikörpern
WO1996000084A1 (en) 1994-06-24 1996-01-04 Torchilin Vladimir P Use of autoantibodies for tumor therapy and prophylaxis
US6001356A (en) * 1995-09-29 1999-12-14 Rush-Presbyterian-St. Luke's Medical Center Method of inhibiting tissue destruction in autoimmune disease using anti-CD44 antibodies
US5783186A (en) 1995-12-05 1998-07-21 Amgen Inc. Antibody-induced apoptosis
UY24389A1 (es) * 1995-12-06 2001-10-25 Karlsruhe Forschzent Composición farmacéutica para el tratamiento de carcinoma de epitelio plano
WO1998006839A1 (en) 1996-07-15 1998-02-19 Human Genome Sciences, Inc. Cd44-like protein
EP0826696B1 (de) * 1996-09-03 2002-05-29 GSF-Forschungszentrum für Umwelt und Gesundheit GmbH Verwendung bi-und trispezifischer Antikörper zur Induktion einer Tumorimmunität
DE19653607A1 (de) 1996-12-20 1998-06-25 Boehringer Ingelheim Int Verfahren zur Diagnose und Therapie von Hodgkin-Lymphomen
DE19708713C2 (de) 1997-03-04 2002-11-28 Boehringer Ingelheim Int Verwendung von anti-CD44 Antikörpern enthaltenden Präparationen zur Behandlung bestimmter Tumore und zur Unterdrückung von Immunreaktionen
US5816468A (en) * 1997-06-24 1998-10-06 Testo Industries Corp. No-idle-striking structure for nailing machines
AU776910B2 (en) 1998-12-08 2004-09-23 Merck Patent Gesellschaft Mit Beschrankter Haftung Modifying protein immunogenicity
US6180357B1 (en) 1999-10-08 2001-01-30 Arius Research, Inc. Individualized patient-specific anti-cancer antibodies
US7947496B2 (en) * 1999-10-08 2011-05-24 Hoffmann-La Roche Inc. Cytotoxicity mediation of cells evidencing surface expression of CD44
US7252821B2 (en) 1999-10-08 2007-08-07 Arius Research Inc. Cancerous disease modifying antibodies
US20050100542A1 (en) * 1999-10-08 2005-05-12 Young David S. Cytotoxicity mediation of cells evidencing surface expression of CD44
US6657048B2 (en) 1999-10-08 2003-12-02 Arius Research, Inc. Individualized anti-cancer antibodies
US20040001789A1 (en) 1999-10-08 2004-01-01 Young David S. F. Cytotoxicity mediation of cells evidencing surface expression of gp96 or precursors thereof
CZ20032787A3 (en) 2001-04-03 2004-03-17 Merck Patent Gmbh Renal cell carcinoma tumor markers
US20030103985A1 (en) 2001-05-18 2003-06-05 Boehringer Ingelheim International Gmbh Cytotoxic CD44 antibody immunoconjugates
AR036154A1 (es) 2001-05-18 2004-08-18 Boehringer Ingelheim Pharma Anticuerpos especificos de cd44v6.
WO2003055515A1 (en) 2001-12-21 2003-07-10 Arius Research, Inc. Individualized anti-cancer antibodies
US20040110933A1 (en) * 2002-09-13 2004-06-10 Dyax Corporation CD44-binding ligands
US7399835B2 (en) * 2004-02-26 2008-07-15 Arius Research Inc. Cancerous disease modifying antibodies
US7319674B2 (en) 2003-07-24 2008-01-15 Cisco Technology, Inc. System and method for exchanging awareness information in a network environment

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1152925A (zh) * 1994-06-08 1997-06-25 贝林格尔·英格海姆国际有限公司 抗cd44v6单克隆抗体
WO2005018667A1 (en) * 2003-08-22 2005-03-03 Arius Research, Inc. Cytotoxicity mediation of cells evidencing surface expression of cd44
WO2005083063A1 (en) * 2004-02-26 2005-09-09 Arius Research, Inc. Cancerous disease modifying antibodies

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
ALLEN CHUAN GAO ET AL.,: "CD44 is a Metastasis Suppressor Gene for Prostatic Cancer Located on Human Chromosome 11p13", 《CANCER RESEARCH》 *
VERA J. M. WIELENGA ET AL.: "Expression of CD44 Variant Proteins in Human Colorectal Cancer is Related to tumor Progression", 《CANCER RESEARCH》 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109402064A (zh) * 2018-11-05 2019-03-01 湖南省肿瘤医院 杂交瘤细胞株及其产生的单克隆抗体和应用
CN109402064B (zh) * 2018-11-05 2021-05-14 湖南省肿瘤医院 杂交瘤细胞株及其产生的单克隆抗体和应用
CN114250200A (zh) * 2021-12-23 2022-03-29 蚌埠医学院 一种非小细胞肺癌脑转移和脊髓转移的动物模型构建方法

Also Published As

Publication number Publication date
ES2444408T3 (es) 2014-02-24
US20060216233A1 (en) 2006-09-28
JP2013165710A (ja) 2013-08-29
CN101432307B (zh) 2013-06-12
US20080274049A1 (en) 2008-11-06
JP2009529497A (ja) 2009-08-20
US7947496B2 (en) 2011-05-24
EP1989233B1 (en) 2013-11-06
TW200731987A (en) 2007-09-01
EP2508536A1 (en) 2012-10-10
US8017117B2 (en) 2011-09-13
AU2007219656A1 (en) 2007-09-07
PL1989233T3 (pl) 2014-04-30
EP1989233A1 (en) 2008-11-12
PT1989233E (pt) 2014-02-11
CY1115212T1 (el) 2017-01-04
JP5247474B2 (ja) 2013-07-24
HK1120527A1 (en) 2009-04-03
SI1989233T1 (sl) 2014-02-28
CA2643708A1 (en) 2007-09-07
CN101432307A (zh) 2009-05-13
WO2007098575A1 (en) 2007-09-07
NZ570776A (en) 2011-03-31
AU2007219656B2 (en) 2013-02-07
EP1989233A4 (en) 2010-05-05
DK1989233T3 (da) 2014-01-13
US20120107233A1 (en) 2012-05-03

Similar Documents

Publication Publication Date Title
US8017117B2 (en) Cytotoxicity mediation of cells evidencing surface expression of CD44
CA2687583C (en) Chimeric and humanized anti-cd44 antibodies that mediate cancer cell cytotoxicity
CN101421395A (zh) 显示cd63表面表达的细胞的细胞毒性介导
CN101675158A (zh) 癌性疾病调节抗体
US8388961B2 (en) Cytotoxicity mediation of cells evidencing surface expression of CD44
KR20090059106A (ko) 암 질환 변경 항체
US20090068182A1 (en) Cytotoxicity mediation of cells evidencing surface expression of CD9
JP2010516631A (ja) 癌性疾患修飾抗体
CN101278055A (zh) 癌性疾病调节抗体
AU2013202753A1 (en) Chimeric and humanized anti-CD44 antibodies that mediate cancer cell cytotoxicity
JP2011528010A (ja) 癌性疾患修飾抗体
CN101663049A (zh) 证明cd44表面表达的细胞的细胞毒性介导
CN101277977A (zh) 癌性疾病调节抗体
CA2653163A1 (en) Methods for the treatment of acute myeloid leukemia
HK1181848A (en) Cytotoxicity mediation of cells evidencing surface expression of cd44
CN101278056A (zh) 癌性疾病调节抗体
HK1120527B (en) Cytotoxicity mediation of cells evidencing surface expression of cd44
CN101292041A (zh) 癌性疾病调节抗体
JP2011520923A (ja) 細胞傷害性抗癌モノクローナル抗体

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1181848

Country of ref document: HK

C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20130710

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1181848

Country of ref document: HK